Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Ophthalmology. 2015 Aug 20;122(10):1967–1975. doi: 10.1016/j.ophtha.2015.06.042

Figure 2.

Figure 2

Distribution of VA for eyes with uveitis assigned to implant (grey) and systemic (white) therapy during the first 54 months of follow-up in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. *Calculated from the subset of eyes with uveitis at enrollment; § 20/20 = 85 letters, 20/40 = 70 letters, 20/200 = 35 letters; † Count Fingers (CF), Hand Motion (HM), Light Perception (LP) denoted as −10 letters; ‡ No Light Perception (NLP) denoted as −25 letters.